AR035935A1 - El empleo de un antagonista del receptor de nk-1 y una composicion farmaceutica que lo comprende - Google Patents
El empleo de un antagonista del receptor de nk-1 y una composicion farmaceutica que lo comprendeInfo
- Publication number
- AR035935A1 AR035935A1 ARP020100393A ARP020100393A AR035935A1 AR 035935 A1 AR035935 A1 AR 035935A1 AR P020100393 A ARP020100393 A AR P020100393A AR P020100393 A ARP020100393 A AR P020100393A AR 035935 A1 AR035935 A1 AR 035935A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- halogen
- hydrogen
- hydroxy
- trifluoromethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01109853 | 2001-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035935A1 true AR035935A1 (es) | 2004-07-28 |
Family
ID=8177209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100393A AR035935A1 (es) | 2001-04-23 | 2002-02-07 | El empleo de un antagonista del receptor de nk-1 y una composicion farmaceutica que lo comprende |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030004157A1 (enExample) |
| EP (1) | EP1385577B1 (enExample) |
| JP (1) | JP4146730B2 (enExample) |
| KR (1) | KR100599134B1 (enExample) |
| CN (1) | CN100398106C (enExample) |
| AR (1) | AR035935A1 (enExample) |
| AT (1) | ATE323531T1 (enExample) |
| AU (1) | AU2002250876B2 (enExample) |
| BR (1) | BR0209151A (enExample) |
| CA (1) | CA2444395C (enExample) |
| DE (1) | DE60210760T2 (enExample) |
| DK (1) | DK1385577T3 (enExample) |
| ES (1) | ES2261657T3 (enExample) |
| MX (1) | MXPA03009720A (enExample) |
| PT (1) | PT1385577E (enExample) |
| WO (1) | WO2002085458A2 (enExample) |
| ZA (1) | ZA200308110B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002089802A2 (en) * | 2001-05-08 | 2002-11-14 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
| US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
| HRP20050664A2 (en) | 2003-01-31 | 2006-12-31 | F. Hoffmann - La Roche Ag | NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-A(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE |
| BRPI0412291A (pt) * | 2003-07-03 | 2006-09-19 | Hoffmann La Roche | antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia |
| ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
| DE602005026669D1 (de) | 2004-07-06 | 2011-04-14 | Hoffmann La Roche | Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten |
| US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ.ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| SI2639224T1 (sl) | 2007-12-07 | 2016-12-30 | Vertex Pharmaceuticals Incorporated | Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin |
| AU2008333845C1 (en) | 2007-12-07 | 2014-01-16 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| CN102245573B (zh) | 2008-02-28 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| BRPI1014125A2 (pt) | 2009-03-17 | 2016-04-12 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica, e, uso de um composto. |
| WO2010119347A1 (en) * | 2009-04-14 | 2010-10-21 | Helsinn Healthcare S.A. | Netupitant for use in treating bladder dysfunction |
| US20120196901A1 (en) * | 2009-10-29 | 2012-08-02 | Merck Sharp & Dohme Corp. | Tertiary amide orexin receptor antagonists |
| LT3150198T (lt) | 2010-04-07 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas |
| PL3067349T3 (pl) | 2013-11-08 | 2018-06-29 | Kissei Pharmaceutical Co., Ltd. | Pochodna karboksymetylopiperydyny |
| BR112016010403A2 (pt) | 2013-11-12 | 2017-08-08 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| CA2968130C (en) | 2014-11-18 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
| WO2019148246A1 (en) * | 2018-02-02 | 2019-08-08 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Parenteral formulations and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
| FR2729951B1 (fr) * | 1995-01-30 | 1997-04-18 | Sanofi Sa | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant |
| CN1265652A (zh) * | 1997-08-06 | 2000-09-06 | 伊莱利利公司 | 用作速激肽受体拮抗剂的2-酰基氨基丙胺化合物 |
| EP1005454A4 (en) * | 1997-08-06 | 2003-01-15 | Lilly Co Eli | 2-ACYLAMINOPROPANAMINE FOR USE AS TACHYKININ RECEPTOR ANTAGONISTS |
| JPH11322748A (ja) * | 1998-03-19 | 1999-11-24 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および用途 |
| PT1035115E (pt) * | 1999-02-24 | 2005-01-31 | Hoffmann La Roche | Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1 |
| WO2000067742A2 (en) * | 1999-05-05 | 2000-11-16 | Warner-Lambert Company | Use of gaba analogues for the modulation of substance p |
| ATE400556T1 (de) * | 2000-07-14 | 2008-07-15 | Hoffmann La Roche | N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten |
| US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
-
2002
- 2002-02-02 CN CNB028087305A patent/CN100398106C/zh not_active Expired - Lifetime
- 2002-02-02 KR KR1020037013798A patent/KR100599134B1/ko not_active Expired - Lifetime
- 2002-02-02 ES ES02719751T patent/ES2261657T3/es not_active Expired - Lifetime
- 2002-02-02 AT AT02719751T patent/ATE323531T1/de active
- 2002-02-02 MX MXPA03009720A patent/MXPA03009720A/es active IP Right Grant
- 2002-02-02 WO PCT/EP2002/001085 patent/WO2002085458A2/en not_active Ceased
- 2002-02-02 DK DK02719751T patent/DK1385577T3/da active
- 2002-02-02 EP EP02719751A patent/EP1385577B1/en not_active Expired - Lifetime
- 2002-02-02 BR BR0209151-8A patent/BR0209151A/pt not_active Application Discontinuation
- 2002-02-02 DE DE60210760T patent/DE60210760T2/de not_active Expired - Lifetime
- 2002-02-02 CA CA2444395A patent/CA2444395C/en not_active Expired - Lifetime
- 2002-02-02 AU AU2002250876A patent/AU2002250876B2/en not_active Expired
- 2002-02-02 PT PT02719751T patent/PT1385577E/pt unknown
- 2002-02-02 JP JP2002583031A patent/JP4146730B2/ja not_active Expired - Lifetime
- 2002-02-07 AR ARP020100393A patent/AR035935A1/es unknown
- 2002-02-08 US US10/071,570 patent/US20030004157A1/en not_active Abandoned
-
2003
- 2003-10-17 ZA ZA2003/08110A patent/ZA200308110B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002250876B2 (en) | 2005-03-03 |
| CA2444395A1 (en) | 2002-10-31 |
| WO2002085458A2 (en) | 2002-10-31 |
| WO2002085458A3 (en) | 2003-10-30 |
| MXPA03009720A (es) | 2004-01-29 |
| DE60210760D1 (de) | 2006-05-24 |
| ES2261657T3 (es) | 2006-11-16 |
| CA2444395C (en) | 2010-12-21 |
| EP1385577A2 (en) | 2004-02-04 |
| ATE323531T1 (de) | 2006-05-15 |
| DE60210760T2 (de) | 2006-11-23 |
| CN100398106C (zh) | 2008-07-02 |
| EP1385577B1 (en) | 2006-04-19 |
| CN1503684A (zh) | 2004-06-09 |
| KR100599134B1 (ko) | 2006-07-12 |
| US20030004157A1 (en) | 2003-01-02 |
| ZA200308110B (en) | 2005-03-30 |
| JP2004529931A (ja) | 2004-09-30 |
| DK1385577T3 (da) | 2006-08-21 |
| JP4146730B2 (ja) | 2008-09-10 |
| KR20040007503A (ko) | 2004-01-24 |
| BR0209151A (pt) | 2004-07-13 |
| PT1385577E (pt) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035935A1 (es) | El empleo de un antagonista del receptor de nk-1 y una composicion farmaceutica que lo comprende | |
| AR037008A1 (es) | El uso del antagonista del receptor nk-1 para la elaboracion de un medicamento para el tratamiento y/o prevencion de lesiones cerebrales, espinales o neuronales y una composicion farmaceutica que comprende uno o mas de dicho antagonista. | |
| YU8703A (sh) | Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1 | |
| GB0128499D0 (en) | Therapeutic agents | |
| AR015595A1 (es) | Compuestos derivados de pirazolo [4,3-d]-pirimidin-7-onas, composiciones farmaceuticas, formulacion veterinaria, uso de dichos compuestos en la preparacionde composicion y formulaciones. procedimientos para su uso, compuestos intermediarios, proceso para la preparacion de los compuestos. | |
| AR033306A1 (es) | Compuestos | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR029614A1 (es) | Derivados de 4-fenil-piridina, su uso, un proceso para prepararlos, y medicamentos que los contienen | |
| AR060729A1 (es) | Compuestos agonistas de los receptores muscarinicos | |
| RU2003102612A (ru) | N-окиси в качестве пролекарств производных 4-фенилпиридина, являющихся натагонистами рецептора nk-1 | |
| AR036115A1 (es) | Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma | |
| ECSP034431A (es) | N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina | |
| AR004735A1 (es) | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| AR049956A1 (es) | DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS. | |
| ME00555A (en) | Tryasolyl tropane derivatives as ccr5 modulators | |
| WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
| AR049739A1 (es) | Derivados de aril-piridina | |
| AR037465A1 (es) | Compuesto derivado de 5-sulfanil-4h-1,2,4-triazol, composicion farmaceutica que lo comprende y proceso para su preparacion en fase liquida | |
| ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
| AR008614A1 (es) | UN PROCEDIMIENTO PARA LA FABRICACIoN DE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE PIRIMIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DELMISMO, QUE TIENE ACTIVIDAD INHIBITORIA DE LA TIROSINA QUINASA, COMPUESTOS DE PIRIMIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y UN PROCEDIMI | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| AR074353A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica. | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| AR024146A1 (es) | Derivados de 4-fenil-pirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |